Literature DB >> 2229313

Parathyroid hormone and cirrhosis of the liver.

W Kirch1, M Höfig, T Ledendecker, H Schmidt-Gayk.   

Abstract

Fifty patients with liver cirrhosis (36 alcoholic, 1 drug-induced, 7 posthepatitic, and 6 cryptogenic) and normal renal function were investigated to determine whether PTH levels in serum, measured using the common midregion human PTH-(44-68) RIA, are elevated in such patients and whether this is related to impaired liver function rather than to the effect of secondary hyperparathyroidism. Their data were compared with those from 25 control subjects. The median PTH level of 462 +/- 18 ng/L (+/- SEM) was significantly increased (P less than 0.01) in cirrhotics compared with that of 236 +/- 13 ng/L in the control group. Significant correlations were found between PTH levels and parameters of liver function such as prothrombin time (r = -0.40; P less than 0.01), albumin as a percentage of total protein (r = -0.48; P less than 0.01), bilirubin (r = 0.35; P less than 0.05), albumin (r = -0.34; p less than 0.05), and cholesterol (r = -0.32; P less than 0.05), but not for antipyrine clearance, suggesting increasing PTH with decreasing liver function. The median calcium level (2.26 +/- 0.03 mmol/L), corrected for changes in albumin, was near the lower limit of the normal range (2.25-2.60), but corrected calcium and PTH were positively correlated (r = 0.33; P less than 0.05), indicating that the elevation is not reactive to calcium depletion. A negative correlation existed between PTH and 25-hydroxy-cholecalciferol (r = -0.49; P less than 0.05), the main circulating metabolite of vitamin D. Normal values in an immunoradiometric assay that detects the whole sequence of human PTH-(1-84) suggest that fragments rather than the intact hormone are responsible for PTH elevations in cirrhosis. The positive correlation between midregion PTH and corrected calcium is probably an artifact of the correction formula. In conclusion, midregion PTH fragments are increased in patients with liver cirrhosis. The reason for this elevation may well be the impaired liver function rather than secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229313     DOI: 10.1210/jcem-71-6-1561

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.

Authors:  Karam A Mahdy; Hanaa H Ahmed; Fathia Mannaa; Azza Abdel-Shaheed
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

2.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

3.  Effects of cirrhosis on bone mineral density and bone metabolism.

Authors:  Mehmet Turkeli; Hakan Dursun; Fatih Albayrak; Nihat Okçu; M Hamidullah Uyanik; Abdullah Uyanik; Rahşan Yıldırım; Mustafa Keleş; Omer Yılmaz
Journal:  Eurasian J Med       Date:  2008-04

4.  High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis-An Observational Study.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha Krishan Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-11-26

5.  Diagnostic Accuracy Study of Intraoperative and Perioperative Serum Intact PTH Level for Successful Parathyroidectomy in 501 Secondary Hyperparathyroidism Patients.

Authors:  Lina Zhang; Changying Xing; Chong Shen; Ming Zeng; Guang Yang; Huijuan Mao; Bo Zhang; Xiangbao Yu; Yiyao Cui; Bin Sun; Chun Ouyang; Yifei Ge; Yao Jiang; Caixia Yin; Xiaoming Zha; Ningning Wang
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

6.  Which factors influence liver stiffness measured by real-time two dimensional shear wave elastography in patients on maintenance hemodialysis?

Authors:  Danijela Zjačić Puljiz; Ivana Kristina Delić Jukić; Marko Puljiz; Lučana Vicelić Čutura; Iva Jerčić Martinić-Ceza; Dorotea Božić; Kristian Podrug; Željko Puljiz
Journal:  Croat Med J       Date:  2021-02-28       Impact factor: 1.351

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.